Stockwatch: Lilly And GW Move Goalposts
This article was originally published in Scrip
Executive Summary
There were few bright spots last week in life sciences, with the NASDAQ Biotech Index finishing down by 4% as it continued, uncharacteristically, to underperform the broad S&P 500 index. The handful of positive announcements from the industry actually look very fragile on closer inspection, perhaps marking new lows for an industry where the integrity of clinical trial announcements and investment bank analysis can no longer be believed in.
You may also be interested in...
Stockwatch: The TIGER That Came To Lilly
The reasons behind Lilly's latest clinical failure had much less to do with the indication and more to do with repeating the past mistakes of Inspire and Sunesis. Unfortunately, that same die has already been cast for the trials of Biogen and Ophthotech that are due to report imminently.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.